DADC
SUPN icon

D.A. Davidson & Co’s Supernus Pharmaceuticals SUPN Stock Holding History

D.A. Davidson & Co’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-18,463
Closed -$611K – 1025
2019
Q2 		$611K Buy
18,463
+4
+0% +$137 0.01% 593
2019
Q1 		$647K Buy
18,459
+1,868
+11% +$69.5K 0.01% 617
2018
Q4 		$551K Sell
16,591
-697
-4% -$30K 0.01% 617
2018
Q3 		$870K Sell
17,288
-81
-0.5% -$4K 0.02% 548
2018
Q2 		$1.04M Buy
17,369
+921
+6% +$47.7K 0.02% 491
2018
Q1 		$753K Buy
16,448
+977
+6% +$40.8K 0.02% 550
2017
Q4 		$617K Buy
15,471
+212
+1% +$8.38K 0.01% 603
2017
Q3 		$610K Buy
15,259
+663
+5% +$28.7K 0.01% 621
2017
Q2 		$629K Buy
14,596
+1,414
+11% +$50.3K 0.01% 560
2017
Q1 		$412K Buy
13,182
+1,336
+11% +$35.8K 0.01% 672
2016
Q4 		$299K Buy
11,846
+4,993
+73% +$112K 0.01% 843
2016
Q3 		$169K Sell
6,853
-91
-1% -$2.06K ﹤0.01% 1012
2016
Q2 		$141K Hold
6,944
– – ﹤0.01% 979
2016
Q1 		$105K Buy
6,944
+2,315
+50% +$30.2K ﹤0.01% 1107
2015
Q4 		$62K Buy
+4,629
New +$71.6K ﹤0.01% 1320

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

D.A. Davidson & Co's SUPN Position: Q3 2019 in Review

D.A. Davidson & Co sold out of Supernus Pharmaceuticals (SUPN) in Q3 2019, closing a stake of 18,463 shares — an estimated $611K sold.

D.A. Davidson & Co first reported a position in SUPN in Q4 2015 and held it in 15 quarters. The position peaked at $1.04M in Q2 2018. 243 funds tracked by Wall St. Rank hold SUPN as of Q3 2019.

  • D.A. Davidson & Co reported no remaining Supernus Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • D.A. Davidson & Co sold 18,463 Supernus Pharmaceuticals shares in Q3 2019, an estimated $611K.
  • D.A. Davidson & Co first reported a position in Supernus Pharmaceuticals in Q4 2015 and held it in 15 quarters.
  • D.A. Davidson & Co's Supernus Pharmaceuticals position peaked at $1.04M in Q2 2018.
  • 243 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2019.

Based on D.A. Davidson & Co's 13F filing for Q3 2019, filed 5 Nov 2019.